期刊
EXPERT OPINION ON DRUG DISCOVERY
卷 14, 期 11, 页码 1161-1174出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/17460441.2019.1652593
关键词
Trypanosoma cruzi sterol pathway; new drug candidates; trypanosome targets; phenotypic screening; artificial intelligence; challenges in Chagas drug discovery
资金
- National Institutes of Health [AI007281-28, HL007737-22, U54 MD007586-31, U54 MD007593-09, U54 MD010722-02, AI080580, P30 AI110527-04]
Introduction: Chagas disease affects 8-10 million people worldwide, mainly in Latin America. The current therapy for Chagas disease is limited to nifurtimox and benznidazole, which are effective in treating only the acute phase of the disease but with severe side effects. Therefore, there is an unmet need for new drugs and for the exploration of innovative approaches which may lead to the discovery of new effective and safe drugs for its treatment. Areas covered: The authors report and discuss recent approaches including structure-based design that have led to the discovery of new promising small molecule candidates for Chagas disease which affect prime targets that intervene in the sterol pathway of T. cruzi. Other trypanosome targets, phenotypic screening, the use of artificial intelligence and the challenges with Chagas disease drug discovery are also discussed. Expert opinion: The application of recent scientific innovations to the field of Chagas disease have led to the discovery of new promising drug candidates for Chagas disease. Phenotypic screening brought new hits and opportunities for drug discovery. Artificial intelligence also has the potential to accelerate drug discovery in Chagas disease and further research into this is warranted.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据